Literature DB >> 12806595

Effect of angiotensin-converting enzyme inhibition on endothelial function and insulin sensitivity in hypertensive patients.

Hakan Tezcan1, Dilek Yavuz, Ahmet Toprak, Ihsan Akpinar, Mehmet Koç, Oguzhan Deyneli, Sema Akalin.   

Abstract

INTRODUCTION: Evidence suggests an association between insulin resistance, hypertension and impaired endothelial function. Studies have shown that insulin resistance precedes the development of hypertension. By improving insulin sensitivity, it may be possible to improve hypertension and the subsequent damage to vessel walls. Some data indicates beneficial effects of angiotensin-converting enzyme (ACE) inhibitors on insulin sensitivity and endothelial function. We aimed to investigate these effects of ACE inhibition in the same group of patients with essential hypertension.
MATERIALS AND METHODS: Nine non-smoking, untreated hypertensive patients (38.3+9 years, 4/5 male/female) and 12 age-matched healthy subjects (35.2+6.7 years, 5/7 male/female) were included in the study. Hypertensive patients were given enalapril maleate (5 40 mg/day) for six months. The following parameters were studied at baseline and at the end of treatment period. Whole body insulin sensitivity was measured by a formula derived from an oral glucose tolerance test and named as the insulin sensitivity index (ISI). Insulin was measured by chemiluminescence and glucose by a glucose oxidase method. Endothelial function was evaluated as flow-mediated dilatation (FMD) of the brachial artery by ultrasonography and expressed as a percentage change relative to baseline diameter. Endothelial- independent vasodilatation was measured after sublingual nitroglycerine.
RESULTS: FMD was impaired in the hypertensive group compared with healthy subjects (7.3+3.1% vs. 15.3+4.8%, p<0.0005), and ISI values were 1.18+0.6 vs. 4.4+0.9 (p<0.0001) respectively. Both insulin sensitivity and FMD improved after the treatment period compared with baseline values, FMD increased from 7.3+3.1% to 16.0+2.9% (p<0.0005) and ISI from 1.18+0.6 to 4.2+1.0 (p<0.0001). FMD and ISI showed a significant positive correlation (r=0.67, p<0.001) in the hypertensive group.
CONCLUSIONS: Patients with essential hypertension have impaired endothelial function and decreased whole body insulin sensitivity compared with healthy subjects. Treatment for six months with enalapril maleate seems to improve both FMD and ISI. This study confirms the beneficial effects of ACE inhibition on both endothelial function and insulin sensitivity tested in the same group of essential hypertensive patients. The mechanism of these favourable effects of ACE inhibition needs to be clarified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12806595     DOI: 10.3317/jraas.2003.012

Source DB:  PubMed          Journal:  J Renin Angiotensin Aldosterone Syst        ISSN: 1470-3203            Impact factor:   1.636


  6 in total

Review 1.  Ace inhibitors as a therapy for sarcopenia - evidence and possible mechanisms.

Authors:  D Sumukadas; M D Witham; A D Struthers; M E T McMurdo
Journal:  J Nutr Health Aging       Date:  2008 Aug-Sep       Impact factor: 4.075

Review 2.  The vascular endothelium in diabetes--a therapeutic target?

Authors:  Kieren J Mather
Journal:  Rev Endocr Metab Disord       Date:  2013-03       Impact factor: 6.514

Review 3.  Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome.

Authors:  Stephan Jacob; Erik J Henriksen
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-12       Impact factor: 3.738

4.  The effect of antihypertensive drugs on endothelial function as assessed by flow-mediated vasodilation in hypertensive patients.

Authors:  Michiaki Miyamoto; Kazuhiko Kotani; Shun Ishibashi; Nobuyuki Taniguchi
Journal:  Int J Vasc Med       Date:  2012-02-29

Review 5.  Comparative Efficacy of Antihypertensive Agents in Flow-Mediated Vasodilation of Patients with Hypertension: Network Meta-Analysis of Randomized Controlled Trial.

Authors:  Hong Ding; Shu Liu; Ke-Xin Zhao; Jie Pu; Ya-Fei Xie; Xiao-Wei Zhang
Journal:  Int J Hypertens       Date:  2022-04-30       Impact factor: 2.434

6.  ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.

Authors:  M L Bots; W J Remme; T F Lüscher; K M Fox; M Bertrand; R Ferrari; M L Simoons; D E Grobbee
Journal:  Cardiovasc Drugs Ther       Date:  2007-08       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.